Introduction of OEP

1. Creativity
Integrity
Solidarity
Integrity
2010
Introduction of
Orient Europharma

2. General Information
Financial Performance
Solidarity
Creativity
Business Unit Performance
Business Development
Integrity
Integrity
p.2

3. Creativity
Integrity
Solidarity
Integrity
GENERAL INFORMATION
p.3

4. OEP near term Strategy
★ Diversity in Product Portforlios
Solidarity
★ Presence in Major Asian Countries
Creativity
★ Collaboration in Product Dev
Integrity
Integrity
p.9

5. Major Business Segment
Oncology
Orient
Nutricare
Pharma
Solidarity
Creativity
OEP
Consumer
Pharma
Health
Integrity
Cosmetic
Integrity
p.12

6. Headquarters & Subsidiaries of
ORIENT EUROPHARMA CO., LTD
Headquarters: Taipei, Taiwan
Solidarity
Creativity
Subsidiaries: Hong Kong
Philippines
Integrity
Malaysia
Integrity
Singapore
China

7. Revenue Contribution from
Division
Adult Nutrition
OEP’s KariMed® Other
1%
Aesthetic &
Adult health Skincare products
supplements Cosmetic
12%
Solidarity
45% 42%
Creativity
Nutrition Ethical
Infant Nutrition Licensing-in & Self
OEP’s Own－Karihome® Development
Integrity
Goat & Cow Series milk
powder
Integrity
p.7

8. Our Sales Force Overview
Countries
Taiwan Singapore Malaysia Hong Kong China Philippines Total
/Region
Solidarity
Hospital 51 2 9 3 0 175 240
Creativity
Specialty 14 2 3 2 0 0 21
Aesthetic 24 0 0 0 0 0 24
Integrity
OTC 43 9 5 7 20 0 84
Integrity
Total 132 13 17 12 20 175 369
8

9. Worldwide Partners
1982
1984
1986
1988
Solidarity
Creativity
1994
1996
1999
2001
Integrity
2003
Integrity
2004
2005
2006 2009 2009 2009
2008
2009
9

10. Creativity
Integrity
Solidarity
Integrity
FINANCIAL PERFORMANCE
p.3

11. 2009 Financial Summary
2009 Total Net Revenue USD $ 121M，10%
growth over 2008
Solidarity
Creativity
2009 EPS $4.04 ， highest among all
listed Taiwan Pharmaceutical company
Integrity
2009 vs 2008 Reveneue
•Singapore +16%
Integrity
•Philippines +11% ( Ranked No. 26 based on IMS revenue)
•Malaysia +5%
•Hong Kong +7%
•China +75%
p.4

12. Unit：
Revenue
Million (USD)
Oversea
140 Taiwan
120
100
Solidarity
80
Creativity
60
40
20
0
Integrity
2005 2006 2007 2008 2009
Integrity
Taiwan 64 70 83 93 100
Oversea 6 9 14 18 21
Total 71 79 96 112 121
p.5

13. Net Profit After Tax
Unit：Million (USD)
9,000,000
8,000,000
7,000,000
6,000,000
Solidarity
Creativity
5,000,000
4,000,000
3,000,000
2,000,000
1,000,000
Integrity
Integrity
-
2005 2006 2007 2008 2009
Net Profit
3,806,500 4,147,250 5,025,969 7,152,031 8,661,969
After Tax
p.13

14. Earning Per Share
Unit：Dollar (TWD)
5
4
Solidarity
3
Creativity
2
1
Integrity
0
2005 2006 2007 2008 2009
Integrity
EPS
2.62 2.64 2.83 3.45 4.04
p.7

15. Creativity
Integrity
Solidarity
Integrity
Leading Company In Taiwan

16. Creativity
Integrity
Solidarity
Integrity
p.15
Only Local among Fastest Growth

17. Creativity
Integrity
Solidarity
Integrity
Top 10 Among Local MNF

18. Creativity
Integrity
Solidarity
Integrity
Top 2 in Mid-sized company in PHL

19. Creativity
Integrity
Solidarity
Integrity
BUSINESS UNIT
PERFORMANCE
p.3

20. Nutricare Highlights
2009 AC Nielson survey ranked，
OEP’s Karihome milk powder
series highest in market share 。
Ranked top 3 in Infant
supplementary Food segment。
Solidarity
Creativity
5% Market share in Special
Dietary Formulae。
Integrity
Integrity
p.13

21. Future Strategy & Direction
Interim Strategy /Market
Development：
Multiple Branding
New Product Development:
Solidarity
Focus on Infant nutritional
Creativity
Need
Expansion on Special dietary
product line
Market Development:
Cont. Expansion in Asia Market
Integrity
Synergy on promotional
Integrity
resource & standardizing
product image.
p.14

22. Pharmaceutical
Product Portfolio focused
cardiovascular
Metabolism
Respiratory
Solidarity
Creativity
Woman’s Health
Central Nervous System
Main drive in 2009 revenue in two major
segment : Cardiovascular & Metabolism 。
Integrity
Integrity
p.22

23. Future Strategy & Direction
Future Strategy:
Continue in expanding market share in cardiovascular &
metabolism market。
Continue expansion in Self-payment or not reimbursement
market。
2010 Product Portfolio :
Solidarity
Q1 :First generic in Immuno suppressant for organ transplant
Creativity
patients。
Q2: Foster for treatment of Asthma 。
Q3: Collaboration with Japanese Pharma for fast acting DM
Type II Disease。
Market Planning:
Integrity
Current Product: Expansion to Hospital/Clinic channel。
Integrity
New Product: Synergy with current product to speed up
Listing。
p.23

24. Oncology
Navelbine IV / Oral for Non-small cell
lung cancer & Breast cancer
Nominated by Pierre Fabre as the best
performing Territory among Pierre
Solidarity
Fabre subsidiary & Licensee for two
Creativity
consecutive years 2008 & 2009
Integrity
Integrity
p.16

25. Future Strategy & Direction
Active collaboration with partners in International clinical trial to
provide the best treatment to the cancer patients in Asia Pacific
Cancer Treatment
Best Supportive Care
Solidarity
Product under Ongoing registration or Clinical Trial：
Creativity
Loramyc® : Oral Candidiasis
Nanoplatin®:Nano technology of Cisplatin for Pancreatic
Cancer.
Multikine®:Head & Neck Cancer Phase III trial scheduled to
commenced in Q3, 2010.
Integrity
Integrity
p.17

26. COSMETIC
Sole Distributor for the world reknown Brand︰
Q-MED︰RESTYLANE ( Hyaulronic Acid Injectable)
Pierre Fabre (France)︰ADERMA，DUCRAY
Dermofarm (Spain)︰CUMLAUDE
Noevir (Japan)︰NOV
Channel Coverage: Hospital, Clinic & Pharmacy。
Solidarity
Creativity
Established in 2002，CAGR : Two digit growth 。
Integrity
Integrity
p.19

27. Future Strategy & Direction
2010 Promotional Strategy：
Expansion in Channel
Introduce new skin care concept from Europe : Organic product
Introduce new aesthetic technology
Solidarity
Creativity
Total Solution！Not just product but total skin care services from in to
out
Integrity
Integrity
p.20

28. Consumer Healthcare
Main Concept : Product Development aroud:
Organic Health supplement
Oral Care
Adult Nutrition in Milk & Cereal
Health Supplement – A series of product under
Solidarity
(KariMed) developed for Skin whitening & Anti-
Creativity
aging 。
Oral Care- (BUCCOTHERM) make from Natural Spring
Water from France以; Total Oral care from Infant to
Adult. Due to its unique taste and chemical free
feature is the first choice in oral care for infants。
Integrity
Adult Nutrition in Milk & Cereal– (Vitaglow )series of
Integrity
milk and cereal co-development Lactalis &Global
Health。
p.25

29. Future Strategy & Direction
Key Strategy in Expansion
Brand Recognition、Channel & Profitbility：
Solidarity
Creativity
Integrity
Innovation Inc Medical Inc
Integrity
activities Distributor
p.26

30. Creativity
Integrity
Solidarity
Integrity
BUSINESS DEVELOPMENT
p.3

31. Licensing - Pipeline Information
Phase 1 Phase II Phase III Registration Marketed
Ella (HRA
Pharma)
Glufast (Kissei)
Hylase
Solidarity
(reimser)
Creativity
Loramyc
(Handok)
B r o n u c k
( S e n j u )
Vido (Senju)
Nanoplatin
(NanoCarrier)
Integrity
Multikine
Integrity
(Cel-Sci)

32. PRODUCTS AVAILABLE FOR EXPORT
ATC Code NCE/NF/Generic Compound Dosage Indication
•A02 •Generic •Granisetron •1mg/ml •Supportive Care
•A02 •Generic •Granisetron •1mg/3ml Therapy
•A10 •Generic •Glibenclamide + •2.5mg + 500mg •Supportive Care
•A10 •Generic Meformin •5mg + 500mg Therapy
•C03 •Generic •Glibenclamide + •0.5mg •Type II DM
•G04 •Generic Meformin •10mg SR •Type II DM
Solidarity
•L04 •Generic •Metolazone •250mg •Diuretic
•Alfuzosin •BPH
Creativity
•N05 •Generic •10mg
•Mycophenolate •Immunosuppressant
•Zeleplon •Insomnia
Integrity
Integrity

33. R&D Developmental Pipeline - 1
2010 2011 2012 2013 2014 2015
Rifampin-
Isoniazid
Capsules
Paroxetine
CR Tablets
Solidarity
Pitavastatin
FC Tablets
Creativity
Vancomycin
CR Capsules
Vancomycin
IR Capsules
Lansoprazole
ODT
Integrity
Miglitol FC
Tablets
Integrity
Zaleplon
Dro-Release

34. R&D Developmental Pipeline - 2
2010 2011 2012 2013 2014 2015
Oxybutynin/
Clonidine
Syrup
Oxybutynin
XL Tablets
Solidarity
Trospium XR
Creativity
Capsules
Ranolazine
ER Tablets
Rizatriptan
ODT
Nelfinavir/
DMC Capsules
Integrity
Fenofibrate
Tablets
Integrity
Zaleplon
10mg
Tablets

35. R&D Developmental Pipeline - 3
2010 2011 2012 2013 2014 2015
Nelfinavir
Capsules
Diltiazem-180
XR
Solidarity
Creativity
Diltiazem-90
XR
Paliperidone
ER Tab
Methy-
lphenidate
Capsules
Rivastigmine
Integrity
Patch
Integrity
Isoniazid

36. Orient Pharma
Manufacturing
Solidarity
Orient
Creativity
Pharma
R& D
Integrity
Integrity
p.31

37. In-house formulation Technologies
Two-Stage Hot-Melt Filling Technology
Transdermal Drug Delivery Technology
Duo-Release Drug Delivery System
Matrix-Controlled Release Drug Delivery System
Solidarity
Creativity
ODT Drug Delivery System
Fast Release Modified Release
Fast Release Modified Release Barrier
a. “CONTROLLED RELEASE OF HYPNOTIC AGENTS” pending. Characteristics:
Integrity
For APIs of low aqueous solubility and to be absorbed systemically.
Integrity
b. “SUSTAINED DELIVERY OF ANTIBIOTICS” pending.
Characteristics: For APIs of high aqueous solubility and not to be absorbed.

38. Project Utilizing Duo – Release System
Partner Product
Solidarity
DURECT (Cupertino, USA) Indication: ADHD
Creativity
University of Southern
Indication: Cancer
California (USC)
Integrity
Indication: Sialorrhoea
Summit PLC (UK)
Integrity
p.36

39. Orient Pharma Facility
Location : Central Science Park
Land Area : 15,200 sq. m (163,400 sq.ft)
Solidarity
Creativity
Plant I : 1,154 sq. m (12,400 sq. ft)
Plant II : 3 floors with 13,500 sq. m (145,100 sq. ft)
Integrity
Utility Building : 630 sq. m (6,770 sq. ft )
Integrity
Design Criteria : FDA, PIC/s & Japanese Standard
p.39

40. Location
Taipei
Taoyuan Plant
Solidarity
Hu Wei Plant
Creativity
Integrity
Airport to Taipei: 35 km (22 mi)
Taipei to Taoyuan: 40 km (25 mi)
Integrity
Taipei to Huwei: 220 km (138 mi)
60 minutes by high speed railway
from Taipei to Huwei
p.40

41. Creativity
Integrity
Solidarity
Integrity
p.41

42. Creativity
Integrity
Solidarity
Integrity
p.42

43. Creativity
Integrity
Solidarity
Integrity
p.43

44. Creativity
Integrity
Solidarity
Integrity
p.44

45. Creativity
Integrity
Solidarity
Integrity
p.45

46. Creativity
Integrity
Solidarity
Integrity
p.46

47. Creativity
Integrity
Solidarity
Integrity
p.47

48. Construction Schedule
Solidarity
2010/03 2010/10
Creativity
2008/12 2010/05
Plant I ready Plant II
Ground Bio-batch
for ready for
breaking production
operation operation
Integrity
Integrity
p.48

49. Landscape
Utility building
Plan
tI
Solidarity
Creativity
Warehouse
Plant II
PASS
BOX
Integrity
QC Lab
Integrity
p.49

50. Solid Dosage Forms
Tablets: Sugar Coated, Film
Coated
Solidarity
Creativity
Hard Shell Capsule
Integrity
1, 2 or 3 Stages Hot Melt Filling ;
Integrity
Hard Shell IR or MR Semisolid
capsule
p.50

51. Equipment
Machine Capacity Brand Type Diameter
Solidarity
Super mixer 190~495 L Glatt VG 600
Creativity
Fluid-bed dryer 520 L
Glatt GPCG PRO 120
High-speed tabletting 28 station 50k~84k
press machine tablet/hr
Fette P1000 Max.16mm
High-speed doulbe
61 station 100k~500k
layer tabletting press
tablet/hr
machine
Integrity
Fette 3200i Max. 25mm
Super Coater 120~150 kg/batch
Integrity
2-Stage Hot Melt
Capsule filling 30k cap/hr Yuan Cheng YC-SC-125FS
machine
51

52. Annual Capacity
Tablet: 800 million
Solidarity
Creativity
Capsule: 320 million
Hot Melt Capsule: 60
Integrity
Integrity
million
p.52

53. Services
Production/Validation
Analysis/Validation
Stabilities Study
Solidarity
Creativity
Clinical trial supply Prod & Packaging
CMC Documentation
Distribution
Integrity
Integrity
Purchasing
p.53

54. Creativity
Integrity
Solidarity
Integrity
THANK YOU!
p.39